Navigation Links
Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache'
Date:4/7/2011

MOUNTAIN VIEW, Calif., April 7, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the publication of results from the Phase 3 FREEDOM-301 study of  LEVADEX™ orally inhaled migraine drug in the peer-reviewed journal 'Headache.' The manuscript, titled MAP0004, Orally Inhaled DHE: A Randomized, Controlled Study in the Acute Treatment of Migraine, has been posted online and will appear in the April edition, Volume 51, Issue 4 of Headache: The Journal of Head and Face Pain. LEVADEX is an investigational acute therapy for migraine that has completed Phase 3 clinical development.

"There is general dissatisfaction with existing acute treatment options for migraine because of slow onset of action, inadequate pain relief, and high recurrence rates. Based on the results from the FREEDOM-301 study, LEVADEX has the potential to address many of the unmet needs of migraine sufferers," said Sheena Aurora, M.D., a FREEDOM-301 clinical study investigator, director of the Swedish Headache Center and assistant professor of neurology at the University Of Washington School of Medicine. 

In the FREEDOM-301 study, the efficacy assessment focused on the four major symptoms of migraine at the standard two hour time point for acute migraine studies. All four co-primary endpoints for LEVADEX were met at two hours:

  • Pain relief was observed in 59% of patients in the LEVADEX treatment group compared with 35% in the placebo group (p<0.0001)
  • Phonophobia free was observed in 53% of patients in the LEVADEX treatment group compared with 34% for the placebo group (p<0.0001)
  • Photophobia free was observed in 47% of patients in the LEVADEX treatment group compared with 27% for the placebo group (p<0.0001)
  • Nausea free was observed in 67% of  patients in the LEVADEX treatment group compared with 59% for the placeb
    '/>"/>

  • SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. MAP Pharmaceuticals to Present Additional Data Analyses From LEVADEX™ FREEDOM-301 Trial at 2010 European Headache and Migraine Trust International Congress
    2. MAP Pharmaceuticals to Present Data Showing Low Migraine Recurrence Rates With LEVADEX™ in FREEDOM-301 Trial
    3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
    7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
    9. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
    10. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... 2014  Decision Resources Group finds that, for ... Brazil and Mexico ... prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist ... current severe cost/coverage constraints. Therefore, new brands of ... launch in these countries—which will considerably expand the ...
    (Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ScriptPro ... Alliance (HITRUST) under its Common Security Framework (CSF). ... Security and Privacy Manager, "We appreciate this rigorous, ... of commitment that this certification signifies. Our business ... ABOUT THE CSF CERTIFICATION PROCESS: ScriptPro,s internal ...
    (Date:8/21/2014)... 21, 2014 BreedIT Corp., ... the exclusive worldwide license holder and distributor of ... and researchers, today is pleased to announce the ... Seach Ltd, a leading Israeli medical Cannabis breeder. ... develop new breeds of medical Cannabis to meet ...
    Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
    ... How Each Tooth Signals the Next to Start GrowingROCHESTER, ... forces determines why mammals develop a single row of ... published today in the journal Science. When completely understood, ... guide efforts to re-grow missing teeth and prevent cleft ...
    ... preventing bone loss focus on early screening and treatmentLAS ... 75 million baby boomers are approaching the age where ... Osteoporosis ( http://orthoinfo.aaos.org/topic.cfm?topic=A00232 ) also contributes ... United States annually. According to new information presented ...
    Cached Medicine Technology:Scientists Discover Why Teeth Form in a Single Row 2Scientists Discover Why Teeth Form in a Single Row 3Scientists Discover Why Teeth Form in a Single Row 4Scientists Discover Why Teeth Form in a Single Row 5Staying One Step Ahead of Osteoporosis 2Staying One Step Ahead of Osteoporosis 3Staying One Step Ahead of Osteoporosis 4
    (Date:8/21/2014)... Newark, NJ (PRWEB) August 21, 2014 Lauren ... winner of the 2014 “Back to the Boardwalk” Facebook sweepstakes. ... vacation at a beautiful four-bedroom beachfront house in Lavallette beginning ... the “Back to the Boardwalk” sweepstakes. Last year, Horizon Blue ... support shore communities after Superstorm Sandy and decided to make ...
    (Date:8/21/2014)... Addiction Centers, a leading national provider of inpatient substance ... addiction, has been named to the Inc. 500 List ... is ranked 7th on the “Top 20 Tennessee Companies” ... in the “Nashville Metro Area” sub-category. With a three-year ... ascended to number 474 on the larger list of ...
    (Date:8/21/2014)... THURSDAY, Aug. 21, 2014 (HealthDay News) -- Using two ... against the disease and may boost efforts to eradicate ... nearly 1,000 children in India found that giving the ... already been given the Sabin live-attenuated oral poliovirus vaccine ... that causes polio. The findings, reported in the ...
    (Date:8/21/2014)... (PRWEB) August 21, 2014 Pleio, ... adherence, is launching a new suite of services ... offerings assist retail pharmacy by applying proven behavior ... classes, resulting in increased medication adherence, higher PDC ... As such, Pleio’s PDC-targeted offerings align retail’s desire ...
    (Date:8/21/2014)... way to use a laser to measure people,s blood ... system to a portable size, the technique could allow ... draw blood. , "We are working hard to turn ... in their daily lives," said Claire Gmachl, the Eugene ... researcher. "With this work we hope to improve the ...
    Breaking Medicine News(10 mins):Health News:American Addiction Centers Named to Inc. 500 List Recognition for Three-Year Sales Growth of 995% 2Health News:Two Polio Vaccines May Give Greater Protection Against Crippling Disease 2Health News:Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy 2Health News:Laser device may end pin pricks, improve quality of life for diabetics 2Health News:Laser device may end pin pricks, improve quality of life for diabetics 3
    ... report prepared by health officials in Tripura has brought to ... that has claimed the lives of nearly 138 infants in ... the report, submitted to the state government, of the 138 ... Gandhi Memorial Hospital here, 29 infants died in birth asphyxia. ...
    ... confirmed that a new hospital for the Bega area will ... that he has directed the Area Health Service and NSW ... hospital. Stating that they will undertake detailed planning of the ... determine the size and type of hospital that is needed, ...
    ... Russia, has reported the deadly H5N1 strain of the ... veterinary authorities.// This is the second case in ... Russia have reported Bird-Flu infections from the beginning of ... Blood samples from the 25 hens that died in ...
    ... symposium titled ‘Challenging Intellectual Property’ will be analyzed and ... ,The Symposium will look into the aspects of ... production in economic development. It will also gauge the ... table, desirous of bringing a change in health research ...
    ... lawyer hundreds of patients who contracted Hepatitis C in the ... of their condition.// This is same as delayed is denied. ... Service ,Frank McGuire, after studying documents obtained through the Freedom ... to find and advise patients and that some had infected ...
    ... to the researchers from Yale School of Medicine it ... in mammals//. Joseph Santos-Sacchi, professor in the Departments of ... said that hearing in marine and other mammals could ... tin). , The study indicates that this ...
    Cached Medicine News:Health News:Government Hospital’s Poor Functioning Claims Lives Of 138 Infant 2Health News:Construction Of A New Hospital In The Bega Area Confirmed 2
    ... five classes of resectoscope electrodes for ... knife, roller bar & ball, and ... electrodes specifically integrated into the ACMI ... with minimal bleeding, increased visibility, and ...
    ... Pro System features a small diameter Percutaneous ... With a reduced outer diameter (11Fr.) and ... can be used as a nephroscope or ... an outer sheath (15.9Fr), it can be ...
    ACMI™ S-Series Resectoscope Systems: Precision instruments designed for superior optical recognition, accurate control, and exceptional durability during steam autoclave sterilization....
    ... Rotating Continuous Flow Resectoscopes enhance ease of ... the working element and telescope to the ... result no rotating components in the ... rotating flow ports, simplifying procedures. The new ...
    Medicine Products: